Minerva Neurosciences, a clinical-stage company focusing on central nervous system disorders, provided its Q2 2026 update reaffirming progress on its lead product candidate roluperidone. With no commercial products yet, the company relies heavily on equity financing and royalties to fund R&D. Its latest quarterly filing confirms a robust liquidity profile with over $24 million in cash and equivalents and a very strong current ratio, positioning it well to advance key clinical trials and regulatory work. Intellectual property protection continues to be a strategic focus amid typical biotech development risks.